Favorable cardiac risk among elderly breast carcinoma survivors

Cancer

Volumn 98, Issue 1, 2003, Pages 2-10

  Lamont, Elizabeth B ^a,c   Christakis, Nicholas A ^b   Lauderdale, Diane S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Acute myocardial infarction (AMI); Breast cancer; Coronary heart disease (CHD); Elderly women; Estrogen; Survivorship

Indexed keywords

ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER RISK; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEART DISEASE; HEART PROTECTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASM STAGING; POSTMENOPAUSE; RISK FACTORS; SEER PROGRAM; TAMOXIFEN; UNITED STATES;

EID: 0037665093     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11467     Document Type: Article

References (46)

1. Gruber CJ, Tschugguel W, Schneeberger C, et al. Mechanisms of disease: production and actions of estrogen. N Engl J Med. 2002;346:340-352.
2. Komaroff AL, Robb-Nicholson C, Woo B. Women's health. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principals of internal medicine. 14th ed. New York: McGraw-Hill, 1998:22.
3. Korenman SG. Oestrogen window hypothesis of the aetiology of breast cancer. Lancet. 1980;1:700-701.
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
5. Henderson BE, Bernstein L. Endogenous and exogenous hormonal factors. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Diseases of the breast. 1st edition. Philadelphia: Lippincott-Raven Publishers, 1996:185-200.
6. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1995;122:9-16.
7. Michaelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ. 1998;316:1858-1863.
8. Grodstein F, Stampfer MJ, Falkeborn M, et al. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology. 1999;10:476-480.
9. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993;329:1141-1146.
10. Olsson H, Hagglund G. Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures. Am J Epidemiol. 1992;136:422-427.
11. Persson I, Adami H, McLaughlin JK, et al. Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control. 1994;5:523-528.
12. Ganry O, Peng J, Dubreuil A. Is there a reduced risk of breast cancer among women with hip fractures? Eur J Epidemiol. 1999;15:313-315.
13. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 1997;336:611-617.
14. Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women. JAMA. 1996;276:1404-1408.
15. Newcomb PA, Tentham-Dietz A, Egan KM, et al. Fracture history and risk of breast and endometrial cancer. Am J Epidemiol. 2001;153:1071-1078.
16. Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol. In press.
17. Ernster VL, Barclay J, Kerlikowske K, et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology, and End Results Program. Arch Intern Med. 2000;160:953-958.
18. Neugut AI, Rosenberg DJ, Ahsan H, et al. Association between coronary artery disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers. 1998;7:869-873.
19. Harlan LC, Abrams J, Warren JL, et al. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002;20:1809-1817.
20. Rutquist LE, Matteson A. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of tamoxifen: the Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1993;85:1398-1406.
21. MacDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. BMJ. 1995;311:977-980.
22. Constantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997;89:776-782.
23. Reis SE, Constantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. J Natl Cancer Inst. 2001;93:16-21.
24. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE (multiple outcomes of raloxifene evaluation) randomized trial. JAMA. 2002;287:847-857.
25. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev. 1999;20:253-278.
26. Cattaneo M, Baglietto L, Zighetti ML, et al. Tamoxifen reduces plasma homocysteine level in healthy women. Br J Cancer. 1998;77:2264-2266.
27. Cushman M, Constantion JP, Tracy RP, et al. Tamoxifen and cardiac risk factors in healthy women. Arterioscler Thromb Vasc Biol. 2001;21:255-261.
28. Clarke SC, Schofield PM, Grace AA, et al. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation. 2001;103:1497-1502.
29. Decensi A, Robertson C, Ballardini B, et al. Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur J Cancer. 1999;35:596-600.
30. Ries LAG, Kosary CL, Hankey BF, et al. SEER cancer statistics review, 1973-1994. Bethesda (MD): National Cancer Institute; 1997 NIH Pub. No. 97-2789.
31. Nattinger AB, McAuliffe TL, Schapira MM. Generalizability of the Surveillance, Epidemiology, and End Results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol. 1997;50:939-945.
32. Hatten J. Medicare's common denominator: the covered population. Health Care Financing Rev. 1980;2:53-64.
33. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623-629.
34. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a Census-based methodology. Am J Publ Health. 1992;92:703-710.
35. Hofer TP, Wolfe RA, Tedeshci PJ, McMahon LF, Griffith JR. Use of community versus individual socioeconomic data in predicting variation in hospital use. Health Serv Res. 1998;33:243-259.
36. Charlson ME, Pompei P, Alex KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
37. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data bases. J Clin Epidemiol. 1992;45:613-619.
38. Zhang J, Iwashyna TJ, Christakis NA. The performance of different lookback periods and sources of information for Charlson comorbidity adjustment in Medicare claims. Med Care. 1999;37:1128-1139.
39. Jordan VC. Estrogen, selective estrogen receptor modulation, and coronary artery disease: something or nothing. J Natl Cancer Inst. 2001;93:2-4.
40. Lauderdale DS, Goldberg J. The expanded racial and ethnic codes in the Medicare data files: their completeness of coverage and accuracy. Am J Public Health. 1996;86:712-716.
41. Mitchell JB, Bubolz T, Paul JE, et al. Using Medicare claims for outcomes research. Med Care. 1994;32:JS38-JS51.
42. Fisher ES, Baron JA, Malenka DJ, Barrett J, Bubolz TA. Overcoming potential pitfalls in the use of Medicare data for epidemiologic research. Am J Public Health. 1990;80:1487-1490.
43. Lauderdale D, Furner SE, Miles TP, Goldberg J. Epidemiological uses of Medicare data. Epidemiol Rev. 1993;15:319-327.
44. Geronimus AT, Bound J, Neidert LJ. On the validity of using Census geocode characteristics to proxy individual socio-economic characteristics. J Am StatAssoc. 1996;91:529-537.
45. Robinson WS. Ecological correlations and the behavior of Individuals. Am Sociol Rev. 1950;15:351-357.
46. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med. 2001;345:99-106.